Evaluation of Prostatic Acid Phosphatase (PAP) as a Candidate Antigen for the Development of Cancer Vaccines for Prostate Cancer
Abstract
The goal of this proposal was to evaluate prostatic acid phosphatase (PAP), a prostate tissue-specific protein, as a candidate tumor antigen for a prostate cancer vaccine. The specific aims of the current proposal were: (1) to determine whether patients with prostate cancer have a pre-existing CD4+ T cell immunity to PAP, and (2) to determine whether patients with prostate cancer have a pre-existing CD8+ T cell responses to PAP and whether PAP-specific CTL derived from individual patients can lyse prostate tumor cells. Results from the studies demonstrate that patients with prostate cancer have detectable Th responses specific for PAP, typically of a Th1 phenotype, implying an immune environment capable of supporting an inflammatory/CTL response specific for PAP, and further suggesting the concept of vaccine strategies targeting PAP, because tolerance to this "self" protein can be overcome in vivo. In addition, 2 Th epitopes capable of eliciting PAP-specific Th responses in vitro were identified, and 3 HLA-A2 epitopes specific for PAP were identified. The identification of these epitopes has lain the foundation for future clinical peptide-based vaccine trials with the goal of eliciting PAP-specific Th and CTL responses.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2001
- Accession Number
- ADA404764
Entities
People
- Douglas G. Mcneel
Organizations
- University of Washington